Studies with larger patient numbers using tumor-specific molecular profiling and tumor heterogeneity analyses are justified to better understand the biology of these tumors and define the optimal treatment approach, and ultimately to answer whether the addition of biological agents in the definitive setting against specific molecular targets such as AR and HER-2/Neu will further improve outcomes for these patients. This evidence concerns the gene ERBB2 and neoplasm.